Know Cancer

forgot password

Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma

Phase 2
18 Years
Not Enrolling
Liposarcoma, Leiomyosarcoma, Fibrosarcoma, Malignant Fibrous Histiocytoma

Thank you

Trial Information

Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma

This is an open label single site Phase II clinical trial to identify a potentially
promising therapy dose for Sunitinib malate, an oral multi-kinase inhibitor. The study drug
will be taken orally once daily on days 1 through 28 of each 42 day cycle. Treatment will be
continued until there is either disease progression or cumulative/acute toxicity which in
the opinion of the treating physician or the trial Principal Investigator (PI) compromises
the ability of the patient to receive treatment or the patient desires to stop treatment.

All patients with unresectable or metastatic STS: leiomyosarcoma, liposarcoma, fibrosarcoma,
and MFH seen at the Moffitt Cancer Center will be screened for eligibility to be enrolled in
the study.

An office visit will be required before the beginning of every cycle every 6 weeks to assess
toxicity and for physical examination. Complete blood count (CBC) and differential,
comprehensive metabolic panel, and electrocardiogram (ECG) will be obtained at every
scheduled visit.

Inclusion Criteria:

- Resolution of all acute toxic effects of prior chemotherapy or radiotherapy or
surgical procedures to National Cancer Institute (NCI) Common Terminology Criteria
for Adverse Events (CTCAE) Version 3.0 grade less than or equal to 1.

- Adequate organ function as defined by the following criteria:

- Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) less
than or equal to 2.5 x local laboratory upper limit of normal (ULN), or AST and
ALT less than or equal to 5 x ULN if liver function abnormalities are due to
underlying malignancy

- Total serum bilirubin less than or equal to 1.5 x ULN

- Absolute neutrophil count (ANC) greater than or equal to1500/microL

- Platelets greater than or equal to 100,000/microL

- Hemoglobin greater than or equal to 9.0 g/dL

- Serum calcium less than or equal to 12.0 mg/dL

- Serum creatinine less than or equal to 1.5 x ULN

- Histologically-proven liposarcoma, leiomyosarcoma, fibrosarcoma, or MFH

- Measurable disease radiographically

- Disease that is deemed surgically unresectable and/or metastatic

- Age greater than or equal to 18 years

- Life expectancy greater than 16 weeks

- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2

- Patients may have had up to 3 prior chemotherapies within 4 weeks of starting the
study treatment.

Exclusion Criteria:

- Major surgery or radiation therapy or chemotherapy within 4 weeks of starting the
study treatment.

- NCI CTCAE version 3 grade 3 hemorrhage within 4 weeks of starting the study

- History of or known brain metastases, spinal cord compression, or carcinomatous
meningitis, or evidence of symptomatic brain or leptomeningeal disease.

- Any of the following within the 6 months prior to study drug administration:

- myocardial infarction,

- severe/unstable angina,

- coronary/peripheral artery bypass graft,

- symptomatic congestive heart failure,

- cerebrovascular accident or transient ischemic attack, or pulmonary embolism

- Ongoing cardiac dysrhythmias of NCI CTCAE greater than or equal to grade 2

- Prolonged QTc interval on baseline electrocardiogram (ECG) > 500 msec.

- Hypertension that cannot be controlled by medications (>150/100 mm Hg despite optimal
medical therapy)

- Prior tyrosine kinase inhibitor therapy

- Pre-existing thyroid abnormality with thyroid function that cannot be maintained in
the normal range with medication

- Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome
(AIDS)-related illness or other active infection

- Concurrent treatment on another clinical trial, except supportive care or
non-treatment trials

- Concomitant use of agents known to induce or inhibit CYP3A4

- Concomitant use of agents metabolized by the cytochrome P450 system

- Ongoing treatment with therapeutic doses of Coumadin (low dose Coumadin up to 2 mg by
mouth [PO] daily for thrombo-prophylaxis is allowed)

- Pregnancy or breastfeeding patients

- Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or study
drug administration, or may interfere with the interpretation of study results, and
in the judgment of the investigator would make the subject inappropriate for entry
into this study.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Number of Participants With Overall Response (OR)

Outcome Description:

Objective Radiographic Response Rate. Response assessments were based on the longest diameter tumor measurements in accordance with Response Evaluation Criteria in Solid Tumors (RECIST).

Outcome Time Frame:

From On Treatment to Off Study - average of 6 months

Safety Issue:


Principal Investigator

Alberto Chiappori, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

H. Lee Moffitt Cancer Center and Research Institute


United States: Institutional Review Board

Study ID:




Start Date:

November 2006

Completion Date:

December 2011

Related Keywords:

  • Liposarcoma
  • Leiomyosarcoma
  • Fibrosarcoma
  • Malignant Fibrous Histiocytoma
  • Sunitinib malate
  • SU011248
  • Soft tissue sarcoma
  • Gastrointestinal stromal tumors (GIST)
  • MFH
  • Tyrosine kinase inhibitor
  • Imatinib mesylate
  • Phase II
  • Histiocytoma
  • Fibrosarcoma
  • Leiomyosarcoma
  • Liposarcoma
  • Histiocytoma, Benign Fibrous
  • Histiocytoma, Malignant Fibrous
  • Sarcoma



H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida  33612